Sign in to view content

Percentage of Patients Maintained on Quarterly Anti-VEGF Dosing for the Treatment of Neovascular Age-Related Macular Degeneration Across Key Clinical Trials

David A. Eichenbaum, MD, FASRS

Video
Published 2018

Related

Injectable Fluocinolone Acetonide Intravitreal Insert Reduces the Need for Adjunctive Treatment in Noninfectious Posterior Segment Uveitis
Sunil Srivastava, MD
Annual Meeting Talks
2018
Comparison of CRISPR-based Genome Editing of VEGF-A as Treatment Strategy for Choroidal Neovascularization
Glenn C. Yiu, MD, PhD
Updates from the Field
2019
Should We Ever Consider Stopping Treatment for Neovascular AMD?
Rahul N. Khurana, MD, FASRS
Updates from the Field
2020

Category: Age-Related Macular Degeneration

See more